Released Nov 12, 2026, after the close
10-Q filed Nov 12, 2026, 43 days after period end · 0001193125-26-458441
What the release said
On November 12, 2026, Assembly Biosciences, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2026.
Assembly Biosciences reported a net loss attributable to common stockholders of $20.3 million, or $0.93 per basic and diluted share, for the three months ended September 30, 2026, compared to $9.2 million, or $0.72 per share, for the same period in 2025.¶2
The company received a $75 million collaboration extension fee from Gilead and exercised its option to participate in a 40% share of U.S. development costs and profits for the HSV helicase primase inhibitor program.¶3¶4
Revenue from collaborative research with Gilead was $3.0 million for the three months ended September 30, 2026, compared to $10.8 million for the same period in 2025.¶5
Cash, cash equivalents and marketable securities were $314.3 million as of September 30, 2026, compared to $320.4 million as of June 30, 2026, and are projected to fund operations into 2029.¶6
The company initiated dosing in a Phase 2 study evaluating ABI-6250 in participants with chronic hepatitis delta infection.¶7
- Net loss attributable to common stockholders
- $20.3 million Three months ended September 30, 2026; compared to $9.2 million for the same period in 2025¶2
- Net loss per basic and diluted share
- $0.93 Three months ended September 30, 2026; compared to $0.72 per share for the same period in 2025¶2
- Revenue from collaborative research with Gilead
- $3.0 million Three months ended September 30, 2026; compared to $10.8 million for the same period in 2025¶5
- Cash, cash equivalents and marketable securities
- $314.3 million As of September 30, 2026; compared to $320.4 million as of June 30, 2026¶6
- Collaboration extension fee received from Gilead
- $75 million Received following the third anniversary of the collaboration¶3
Same quarter
| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $2.96M | $10.79M | $6.85M | $0.00 |
| Net Income | -$20.26M | -$9.20M | -$9.61M | -$14.42M |
| EPS Diluted | -$0.93 | -$0.72 | -$1.51 | -$3.29 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Assembly Biosciences, Inc. · CIK 1426800 · Engraved from SEC EDGAR